Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study

[1]  Gary H Lyman,et al.  American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Roden,et al.  Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[3]  J. Cuzick,et al.  Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. , 2014, The Lancet. Oncology.

[4]  B. Dawson-Hughes,et al.  The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  M. Aapro,et al.  Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  L. Strong,et al.  Long-term risk of medical conditions associated with breast cancer treatment , 2014, Breast Cancer Research and Treatment.

[7]  F. Sung,et al.  Fracture in Asian Women with Breast Cancer Occurs at Younger Age , 2013, PloS one.

[8]  T. Field,et al.  Fracture Risk in Older, Long‐Term Survivors of Early‐Stage Breast Cancer , 2013, Journal of the American Geriatrics Society.

[9]  Rashmi Kumar,et al.  NCCN Task Force Report: Bone Health in Cancer Care. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  C. V. Van Poznak,et al.  The management of osteoporosis in breast cancer survivors. , 2012, Maturitas.

[11]  A. Giobbie-Hurder,et al.  Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Oddom Demontiero,et al.  Aging and bone loss: new insights for the clinician , 2012, Therapeutic advances in musculoskeletal disease.

[13]  G. Tomlinson,et al.  Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. , 2012, The Lancet. Oncology.

[14]  D. Forman,et al.  Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study , 2011, British Journal of Cancer.

[15]  A. Kearns,et al.  Update on medications with adverse skeletal effects. , 2011, Mayo Clinic proceedings.

[16]  U. P. S. T. Force,et al.  Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement , 2011, Annals of Internal Medicine.

[17]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[18]  M. Holick,et al.  Diagnosis and treatment of osteopenia , 2010, Reviews in Endocrine and Metabolic Disorders.

[19]  R. Chlebowski,et al.  Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women’s Health Initiative , 2009, Osteoporosis International.

[20]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[21]  J. Cuzick,et al.  Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  E. Perez,et al.  Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Blomqvist,et al.  Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Ritenbaugh,et al.  Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer , 2005, Cancer.

[25]  P. Lønning,et al.  Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. M. López,et al.  Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. , 2005, Archives of internal medicine.

[27]  L. Rutqvist,et al.  Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Lamont,et al.  Low risk of hip fracture among elderly breast cancer survivors. , 2003, Annals of epidemiology.

[29]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Mouridsen,et al.  Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.